

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

1 Nagendrakumar Balasubramanian Singanallur^{1†}, Petrus Jansen van Vuren^{1†}, Alexander J
2 McAuley^{1†}, Matthew P Bruce¹, Michael J Kuiper², StellaMay Gwini^{3,4}, Shane Riddell¹, Sarah
3 Goldie¹, Trevor W Drew¹, Kim R Blasdell¹, Mary Tachedjian¹, Shruthi Mangalaganesh^{1,5},
4 Simran Chahal¹, Leon Caly⁶, Julian D Druce⁶, Jennifer A Juno⁷, Stephen J Kent⁷, Adam K
5 Wheatley⁷, Seshadri Vasani^{1,8*}

6 ¹Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial
7 Research Organisation (CSIRO) Health and Biosecurity, Geelong, VIC 3220, Australia

8 ²Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands 3008,
9 VIC, Australia

10 ³Biostatistics Support Service, Barwon Health, Geelong, VIC 3220, Australia

11 ⁴School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004,
12 Australia

13 ⁵Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia

14 ⁶Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for
15 Infection and Immunity, Melbourne, VIC 3000, Australia

16 ⁷Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty
17 Institute for Infection and Immunity, Melbourne, VIC 3000, Australia

18 ⁸Department of Health Sciences, University of York, York, YO10 5DD, United Kingdom

19 [†]These authors have contributed equally to this work and share first authorship

20 ***Correspondence:**

21 Prof. Seshadri S. Vasani, vasan.vasan@csiro.au; orcid.org/0000-0002-7326-3210

22 Abstract

23 Plasma samples taken at different time points from donors who received either AstraZeneca
24 (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19)
25 vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern
26 and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50%
27 neutralizing antibody titres (NT₅₀) against Delta and VIC31 at 6 months compared to 2 weeks after
28 the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of
29 Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres
30 below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks
31 after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold
32 lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender
33 were not found to significantly impact our results. These observations indicate that vaccine matching
34 may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient
35 neutralising antibodies against emerging variants of concern, especially Omicron, amidst the
36 challenges of ensuring vaccine equity worldwide.

37 **Keywords: AlphaFold; BA.1.1; biomolecular modelling; COVID-19; neutralising antibody**
38 **titres; SARS-CoV-2; Spike protein; variants of concern; vaccines; vaccine matching**

Neutralization of SARS-CoV-2 Omicron

39 Introduction

40 The novel coronavirus disease-19 (COVID-19) pandemic caused by the severe acute
41 respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in circa 420 million cases and 6
42 million deaths, and is yet to be brought under control [1]. Only 14.2 vaccine doses have been
43 administered per 100 people in ‘low-income countries’; for ‘lower middle income countries’
44 excluding India the number is 81.6 doses per 100 people [2]. Thus, half the world’s population is still
45 receiving the first dose of a COVID-19 vaccine and is very vulnerable. Although vaccines can reduce
46 the likelihood of infection, re-infection and disease severity in individuals, and to an extent
47 community transmission, the continuous emergence of SARS-CoV-2 variants of concern (VOC) has
48 frustrated global response efforts and highlighted the importance of continued assessment of vaccine
49 efficacy. The World Health Organization has declared 5 VOC to date, viz. Alpha (18 December
50 2020), Beta (18 December 2020), Gamma (11 January 2021), Delta (11 May 2021), Omicron (26
51 November 2021), of which Delta and Omicron are currently of the greatest concern and two variants
52 of interest (VOI) viz. Lambda (14 June 2021) and Mu (30 August 2021) [3].

53 While studies on T-cell responses will provide a more holistic picture of vaccine-induced
54 efficacy, assessment of neutralising antibody reactivity against emerging VOC, such as Omicron
55 (B.1.1.529, referred to as BA.1 henceforth), can help inform near-term public health response. This is
56 especially important for the vaccines manufactured by Pfizer, Moderna, and AstraZeneca, as one or
57 more of these three are approved in 192 countries (which does not include the People’s Republic of
58 China), representing 77% of the world’s population [2]. In this study we have assessed the ability of
59 human plasma samples collected from vaccinated donors at different timepoints to neutralise the
60 current two most globally-prevalent VOC (Delta and Omicron) in comparison with a reference
61 isolate used in previous studies (VIC31; [4]). We have also bolstered our interpretation using *in silico*
62 modelling of the respective Spike proteins, and outlined our thoughts on future follow-up studies.

63 Materials and Methods

64 SARS-CoV-2 Stock Generation and Characterisation

65 Three SARS-CoV-2 isolates, VIC31 (hCoV-19/Australia/VIC31/2020 containing D614G
66 mutation), Delta variant of concern (hCoV-19/Australia/VIC18440/2021), and Omicron BA.1.1
67 variant of concern (hCoV-19/Australia/VIC28585/2021) were provided by the Victorian Infectious
68 Diseases Reference Laboratory (VIDRL; Melbourne, Australia). Virus stocks were propagated and
69 titrated in Vero E6 cells (American Type Culture Collection (ATCC), Manassas, VA, USA) prior to
70 use as previously outlined in [5]. Briefly, VeroE6 cells were grown in 150 cm² flasks in Dulbecco’s
71 Modified Eagle Medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS), 2mM
72 GlutaMAX supplement, 100U/mL penicillin, and 100 µg/mL streptomycin (all components from
73 ThermoFisher Scientific; Scoresby, VIC, Australia) until >80% confluent. Virus isolates were diluted
74 1:100 in DMEM (containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and 100
75 µg/mL streptomycin), and 5 mL was used to inoculate Vero E6 cells for 1 hr at 37°C/5% CO₂ before
76 additional media was added to the flask. The flasks were incubated at 37°C/5% CO₂ for 48 h (for
77 VIC31 and Delta) or 72 hr (for Omicron) before supernatant was clarified at 2,000 x g for 10 min,
78 and harvested and stored in 1 mL aliquots at -80 °C.

79 Identity of virus stocks were confirmed by next-generation sequencing using a MiniSeq
80 platform (Illumina, Inc; San Diego, CA, USA). In brief, 100 µL cell culture supernatant from
81 infected Vero E6 cells was combined with 300 µL TRIzol reagent (Thermo Fisher Scientific) and

Neutralization of SARS-CoV-2 Omicron

82 RNA was purified using a Direct-zol RNA Miniprep kit (Zymo Research; Irvine, CA, USA). Purified
83 RNA was further concentrated using an RNA Clean-and-Concentrator kit (Zymo Research), followed
84 by quantification on a DeNovix DS-11 FX Fluorometer. RNA was converted to double-stranded
85 cDNA, ligated then isothermally amplified using a QIAseq FX single cell RNA library kit (Qiagen,
86 Hilden, Germany). Fragmentation and dual-index library preparation was conducted with an Illumina
87 DNA Prep, Tagmentation Library Preparation kit. Average library size was determined using a
88 Bioanalyser (Agilent Technologies; San Diego, CA, USA) and quantified with a Qubit 3.0
89 Fluorometer (Invitrogen; Carlsbad, CA, USA). Denatured libraries were sequenced on an Illumina
90 MiniSeq using a 300-cycle Mid-Output Reagent kit as per the manufacturer's protocol. Paired-end
91 Fastq reads were trimmed for quality and mapped to the published sequence for the SARS-CoV-2
92 reference isolate Wuhan-Hu-1 (RefSeq: NC_045512.2) using CLC Genomics Workbench version 21
93 from which consensus sequences were generated. Stocks were confirmed to be free from
94 contamination by adventitious agents by analysis of reads that did not map to SARS-CoV-2 or cell-
95 derived sequences.

96 **Human Plasma Samples**

97 Blood samples in EDTA blood collection tubes (BD Biosciences, Australia) were collected
98 from healthy volunteers, aged between 25-70 (both female and male), who received COVID-19
99 vaccine manufactured by either AstraZeneca (Vaxzevria/AZD1222; University of Oxford-
100 AstraZeneca, Oxford/Cambridge, UK), Pfizer (Comirnaty/BNT162b2; BioNTech-Pfizer, Brooklyn,
101 New York, USA), or Moderna (Spikevax/mRNA-1273; Moderna Inc, Cambridge, MA, USA) (**Table**
102 **1**). AstraZeneca vaccine was advised for the age group >60 [6]. Plasma was separated and stored at -
103 70°C until use. The study protocols were approved by institutional ethics committees of the Peter
104 Doherty Institute, Melbourne Australia [University of Melbourne Central Human Research Ethics
105 Committee (2021-21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID
106 2021_123_RR). Biosafety protocols for handling the human samples and the infectious agents were
107 approved by the Institutional Biosafety Committee of ACDP, Geelong before infectious work
108 commenced. Blood samples were collected on the day of vaccination (baseline; pre-1st dose) and 2
109 weeks post second dose (2wk-2nd dose) for all the vaccine groups and after six months of 2nd dose
110 (6mo-2nd dose) and two weeks post third dose (2wk-3rd dose) for the Pfizer group.

111 **Live-Virus Neutralisation Assays**

112 Virus neutralization assays (VNT) were carried out using Vero E6 cells as described previously
113 [5]. Briefly, each plasma sample for the three vaccines was diluted 1:10 in Dulbecco's Phosphate
114 Buffered Saline (DPBS; Thermo Fisher Scientific, Waltham, MA, USA) in a deep-well plate,
115 followed by a two-fold serial dilution up to 1:1,280. The dilution series for each plasma sample was
116 dispensed into triplicate columns of a 96-well plate (one plate per isolate), for a total volume of 50 μ l
117 per well. For the plasma-containing wells, 50 μ l virus diluted in DMEM (Thermo Fisher Scientific,
118 Waltham, MA, USA) containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and
119 100 μ g/mL streptomycin to contain approximately 100 TCID₅₀ (checked by back-titration) was added
120 to each well. The plates were incubated at 37°C/5% CO₂ for 1 h to allow neutralization complexes to
121 form between the antibodies present in the plasma and the virus. A positive control serum was
122 included to confirm the reproducibility of the assay. At the end of the incubation, 100 μ l VeroE6
123 cells were added to each well and the plates were returned to the incubator for 4 days. Each well was
124 scored for the presence of viral CPE, readily discernible on Day 4 post-infection. NT₅₀ neutralization
125 titres calculated using the Spearman-Kärber formula [7], and transformed to log₂ values for analysis.

Neutralization of SARS-CoV-2 Omicron

126 Replicates that did not show neutralisation at 1:10 were scored <1:10 dilution and assigned a value
127 1:5 for statistical analysis in line with the current best practice [8].

128 *In silico* Modelling

129 Molecular models were made of the trimeric Omicron Spike protein from residues 13 to 1160
130 (omitting the transmembrane domain) consistent with variant BA.1.1 and including glycosylation to
131 visualize structural changes from the original strain. ‘AlphaFold’ [9] was used to reconstruct the N-
132 terminal domain due to insertions and deletions. Models were built to include the ‘up’ and ‘down’
133 conformations of the Receptor Binding Domain (RBD, residues 330-530) as well as the human
134 angiotensin converting enzyme 2 (ACE2) receptor. Building upon our previous work, [10] models
135 were solvated and simulated using ‘NAMDv2.14’ software [11] for over 200 nanoseconds before
136 visual assessment of changes to surface epitopes and receptor binding interfaces. More modelling
137 details included in Supplementary Methods.

138 Statistical Analysis

139 The VNT data were grouped based on vaccines, sex (female and male), and age groups (<35 –
140 young; 35-60 – middle and >60 – senior). Both one-way and two-way Analysis of Variance
141 (ANOVA) were used to test the statistical differences between vaccines, sex, age, day post
142 vaccination/booster, variants, and their interactions. Levene’s test for Homogeneity of Variance was
143 performed before two-way ANOVA. If the ANOVA results returned a p-value of <0.05, a *post hoc*
144 test with a Tukey’s range test (Tukey’s Honestly Significant Difference) was performed to measure
145 the interactions between two variables. Plots were drawn using ‘ggplot2’ and all statistical
146 procedures used the ‘car’ and ‘lme’ libraries in R [12]. Longitudinal data for continuous outcomes in
147 multiple vaccine groups were compared using a linear mixed effects model. Subject identification
148 number was added as a random variable while day post vaccination/booster (as a factor) and vaccine,
149 sex and age groups and the interactions were considered as explanatory variables. In all models,
150 explanatory variables were selected based on the lowest Akaike Information Criterion (AIC) using
151 forward selection.

152 Results and Discussion

153 Neutralisation of Delta and Omicron Variants of Concern

154 **Table 1** shows the median ages for AstraZeneca sample donors are 57.5 compared to 38.5 for
155 Moderna, and 33 for Pfizer vaccine donors respectively, the reasons for which are as follows. The
156 Australian Technical Advisory Group on Immunisation (ATAGI) changed its recommendations
157 regarding the AstraZeneca vaccine following reports of thrombotic thrombocytopenia syndrome
158 (TTS) emerging from vaccinated adults [13]. It is worth noting that some individuals younger than 60
159 have received AstraZeneca vaccine following an assessment by a qualified health professional and
160 with a verbal or written consent as provisioned by the Department Health, Government of Australia
161 [6], but there is no brand preference for people aged 60 years and above because the benefits
162 outweigh the risk of TTS in this age group. As a result, samples predominantly originated from
163 young and middle-aged individuals for the Moderna and Pfizer vaccines, and from middle-aged and
164 senior adults for the AstraZeneca vaccine. Given the large age range for the Pfizer vaccine, for this
165 manuscript we classified the age groups in to young (<35 age), middle (35-60) and senior (>60). We
166 chose 35 as the cut-off for middle age as it generally corresponds to parents of teen aged children and
167 is used in metrics such as the Peterson-KFF health System Tracker [14] which has identified COVID-

Neutralization of SARS-CoV-2 Omicron

168 19 as the second and third most important cause of death of people who are over and under 35,
169 respectively. In Australia, Moderna vaccine was approved for use relatively recently (9 August
170 2021), while a third dose of the AstraZeneca is only approved in exceptional circumstances, therefore
171 this study did not have access to third-dose samples for these vaccines.

172 Calculation of fold changes using the data presented in **Table 2** and **Figure 1**, demonstrate that
173 for the Pfizer vaccine there was an 8.2- and 5.5-fold reduction in NT₅₀ titres against VIC31 and Delta
174 respectively 6 months after second dose administration (compared to two weeks), while the average
175 titre against Omicron decreased from an estimated 1:6.3 (only 4/15 samples had quantifiable
176 neutralization) to below assay detection limit for all samples at the same time points. Subsequently
177 there was a 25.5- and 24.7-fold increase in titres against VIC31 and Delta respectively two weeks
178 after a third dose administration (compared to 6 month post-second dose), while the average titre
179 against Omicron increased from below assay detection limit to 1:48.5 at the same time points.
180 Because of the aforementioned limitations, calculation of such fold changes for AstraZeneca and
181 Moderna were not possible. However, it is worthwhile to compare their neutralisation titres two
182 weeks post-second dose relative to the Pfizer vaccine samples. Across all three variants, we did not
183 find any significant difference between Pfizer and Moderna vaccines by 2nd week post second dose of
184 the vaccines (**Supplementary Table S1**).

185 ANOVA and Linear Mixed Models (*lm* and *lmer*) analyses were used to investigate the
186 interactions of age, sex, vaccine, and day post vaccination/booster with neutralising antibody titres to
187 the three different virus variants (**Supplementary Text S1**). One-way and two-way ANOVA
188 analyses showed that, for all vaccines (Pfizer, Moderna and AstraZeneca), day post
189 vaccination/booster and virus variant were the main contributors to differences in neutralising
190 antibody responses, while age and sex did not have significant effects. Based on ANOVA analysis
191 there was no significant difference in neutralising titres based on age or sex for any of the vaccines
192 (**Supplementary Tables S2 & S3; Figure 2A-C**). However, based on Linear Mixed Models (*lm*)
193 analysis, younger individuals tended to have higher neutralising antibody titres (**Supplementary**
194 **Tables S4 & S5; Figure 3A-C**). The titres were dependent on the vaccine, day post-vaccination and
195 variant ($p < 0.001$) and to an extent the age where antibody titres in young showed statistically
196 significant difference when compared to the middle and senior age groups ($p = 0.022$). The antibody
197 titres against Omicron have a negative slope and indicating that there is poor neutralisation with the
198 variant.

199 In line with recent findings in similar studies by other groups [15,16], Omicron titres were
200 significantly lower than VIC31-D614G and Delta titres at all time points and regardless of vaccine,
201 highlighting the concern of poor protection to Omicron following vaccination by any of the three
202 leading vaccines. One shortcoming of our data is the lack of later samples and post-boost (third
203 vaccination) from individuals vaccinated with AstraZeneca and Moderna vaccines. However, the data
204 available from Pfizer vaccinated individuals at 6 months after receiving their second dose indicate a
205 significant waning of immunity to all three variants over this period. Neutralising antibody levels to
206 Omicron were low or undetectable in most individuals two weeks after receiving two Pfizer doses,
207 and below the assay limit of detection in all samples tested at 6 months after the second dose.
208 However, at two weeks after the booster vaccination (third Pfizer dose), a significant booster effect in
209 neutralising titres was noted to all three variants. This highlights the importance of the need for a
210 booster (third) vaccine dose for ongoing protection against D614G and Delta variants, but more
211 importantly that two doses are insufficient to stimulate significant neutralising protection against
212 Omicron BA.1, therefore making the third dose essential. The cause of better protection against
213 Omicron BA.1 following three doses of vaccine incorporating Spike protein lacking Omicron

Neutralization of SARS-CoV-2 Omicron

214 specific mutations, is likely due to higher overall neutralising titres due to a booster effect despite
215 neutralising antibodies to certain epitopes being circumvented.

216 Linear Mixed Model analysis of the variance between variables confirms the ANOVA analyses
217 which showed that day post vaccination/booster and virus variant are the major contributors to titre
218 differences, but further shows that there was a significant difference in neutralising titres elicited by
219 the three different vaccines, mostly due to poor responses to the AstraZeneca vaccine. This analysis
220 model further suggests that younger individuals (aged less than 35 years) are likely to have a stronger
221 neutralising antibody response than older individuals, but we concede that this finding might be
222 confounded by the distribution of the ages within the vaccine groups. This might also explain the
223 poorer responses in the AstraZeneca group because of the vaccine advice in Australia (AstraZeneca
224 mostly used in the older age group).

225 *In silico* modelling and analysis

226 From structural perspectives, there are significantly more mutations in the Spike protein of the
227 Omicron variant shown in **Figure 4A**, (37 mutations in the BA.1 variant, 32 in the BA.2 variant
228 including insertions and deletions), compared to the Delta variant (10 mutations), while only one in
229 the VIC31 strain (D614G). The Omicron mutations contribute to its ability to circumvent vaccine or
230 infection induced neutralising antibody responses [15,16]. Three of these mutations (G142D, T478K
231 and D614G) are common to Delta and Omicron, however we have previously shown experimentally
232 and through *in silico* modelling that D614G has no significant impact on vaccines [4]. In the receptor
233 binding domain (RBD) of the Spike protein alone, which is most immunologically exposed in its 'up'
234 configuration and critical for ACE2 binding, there are 15 and 17 mutations in the Omicron BA.1 and
235 BA.2 variants compared to only 2 in Delta as shown in **Figures 4A & C**. Many of the observed
236 Omicron mutations by our analysis appear to be immune evasive, as they do not appear to be at the
237 ACE2 binding interface and represent a significant change in the residue characteristics; in the RBD,
238 these include N440K, K417N, S477N, T484K, and E484A.

239 Interestingly our isolate VIC28585 belongs to the BA.1.1 sub-lineage as it also contains the
240 R346K spike mutation, which possibly further decreases antibody neutralization based on the
241 reduced binding of class 2 antibodies in theoretical studies with the Mu variant of interest [17]. Next-
242 generation sequencing results also indicated the presence of additional Spike mutations S373P and
243 S375F in our VIC28585 isolate at frequency exceeding 99.8%; these two mutations with Grantham
244 scores of 74 (moderately conservative change) and 155 (radical change) respectively are near the
245 S371L Spike mutation characteristic to BA.1 which has a Grantham score of 145 (moderately radical
246 change). Thus, we have investigated the neutralising responses to Omicron BA.1.1 in individuals
247 vaccinated with three leading COVID-19 vaccines and compared these neutralising titres to those
248 against an early SARS-CoV-2 isolate with the D614G mutation (VIC31), and the Delta variant
249 (B.1.617.2) that subsequently became the dominant variant worldwide prior to Omicron's
250 emergence. For example, on 11 December 2021 the ratio of Delta : BA.1 : BA.1.1 : BA.2 : Other in
251 USA (where extensive data is available from the CDC; [18]) was 92.5 : 5.2 : 2.2 : 0 : 0.2, and this
252 steadily changed over two months so that on 12 February 2021 the ratio was 0 : 22.9 : 73.2 : 3.9 : 0.
253 This shows that BA.1.1, used in our study, could emerge as the dominant variant although we need to
254 wait for more comprehensive data from around the world – as of 16 February 2022, 719,364
255 sequences of BA.1 were reported from 139 countries, while 410,015 sequences of BA.1.1 were
256 reported from 127 countries.

Neutralization of SARS-CoV-2 Omicron

257 Other Omicron mutations are likely to confer increased binding affinity to ACE2 by increasing
258 molecular interactions such as salt bridges and pi-stacking [9]; these mutations include Q493R and
259 Q498R (increasing salt bridge interactions with ACE2's D38 and E35) and N501Y (also seen in
260 Alpha, Beta and Gamma variants, pi-stacking with ACE2's Y41, shown in **Supplementary Figure**
261 **S1**. A cluster of mutations S371L, S373P and S375F, interestingly appear co-located with Y505H in
262 adjacent RBD domains in the 'down' position. These serine mutations, as well as significantly
263 altering epitope presentation of the RBD domain by creating a more rigid structural motif, may allow
264 H505 to interact with the adjacent F375, potentially modulating 'up'/'down' conformations via the
265 ionizable H505, (pKa of 6.0). This structural change may coincide with the observed Omicron
266 preference of infection to the bronchus, where pH is usually lower at 5.5 to 6.5, compared to the lung
267 [19,20] (**Supplementary Figure S2**).

268 With the large number of mutations, it is unsurprising that the Omicron variant displays the
269 observed antibody evasion and replicative advantage over earlier variants [21], as experimentally
270 observed in our study. Our biomolecular modelling shows sufficient distinction between BA.1 and
271 BA.2, therefore future studies should experimentally compare the two.

272 **Public Health Implications and Future Studies**

273 The data we present here highlight the importance of booster vaccination for adequate
274 protection against newly emerging variants such as Omicron BA.1. Further studies are needed to
275 perform similar analyses of neutralising titres in individuals receiving "heterologous" booster doses,
276 e.g., initial AstraZeneca vaccination followed by Moderna or Pfizer boost, or Pfizer-Moderna /
277 Moderna-Pfizer.

278 In the early days of the pandemic, the scientific prediction was that SARS-CoV-2 will have a
279 mutation rate similar to SARS-CoV ($0.8-2.4 \times 10^{-3}$) thanks to the 3'-to-5' exoribonuclease
280 'proofreading mechanism' in coronaviruses [22], which was thought to result in a reduction in the
281 mutation rate ($\sim 10^{-6}$ per site per cycle) compared to influenza ($\sim 3 \times 10^{-5}$ per site per cycle) [23,24].
282 Therefore, it was predicted that vaccine matching may not be required as frequently as seasonal
283 influenza (once a year each for Northern and Southern hemispheres), although this was hard to say
284 definitively because SARS-CoV-2's genetic drift was uncertain with respect to the long-lasting
285 efficacy of vaccine candidates then under development [25]. Early studies, for instance between 1
286 February to 1 May 2020 seemed to confirm the mutation rate prediction with a median estimate of
287 1.12×10^{-3} per site-year ([26]; we believe their upper 95% confidence interval should read 1.85×10^{-3}).

288 Two years on, we have increasing evidence, including from this work, that the primary
289 immunization schedule should consist of three rather than two doses, and indeed many countries are
290 redefining 'fully vaccinated' status as three doses of these vaccines [27]. It is early to speculate on
291 annual boosters beyond the third dose, although Israel has started to expand its fourth dose
292 administration to groups beyond the immunocompromised [28,29]. These developments make it all
293 the more important to ensure vaccine equity across the world so everyone is adequately protected,
294 and highlight the potential need for vaccine matching to increase protection against infection.
295 Vaccines using Spike as the primary antigen should consider including mutations common to BA.1,
296 BA.1.1, and BA.2; development of vaccines with additional antigens, other than Spike, targeting
297 more conserved viral factors should also be explored. This view is further supported by a recent
298 preprint currently under peer review suggesting that, although a fourth dose restored anti-Omicron
299 BA.1 neutralising antibody titres to a level observed post-third dose, breakthrough Omicron
300 infections were common with high virus titres, albeit with very mild clinical signs [29].

Neutralization of SARS-CoV-2 Omicron

301 In this context, it is important to explore vaccines that can better withstand mutations to the
302 Spike protein better, and ideally have less dependence on cold chain. In addition to repeating this
303 work with Omicron BA.2, it is also important to explore the benefits of T cell immunity and
304 heterologous boosting (which are beyond the scope of this paper, but see for instance these studies
305 [30-33]. Another aspect worth exploring is intranasal administration of selected vaccines. In the
306 earliest study (conducted from March 2020) looking at intranasal administration of the AstraZeneca
307 vaccine [34], we found that although neutralising antibody titres were 2-fold lower in ferrets
308 receiving two doses of this vaccine intranasally compared to the intramuscular route, the former was
309 more protected using virus shedding as an infection metric [35]. These findings were subsequently
310 confirmed in hamsters and non-human primates [36], and also reportedly led to a small clinical trial
311 in 30 humans [37]. We feel that the intranasal route, and the role of mucosal immunity, needs to be
312 explored more comprehensively given that the AstraZeneca vaccine has the widest reach (183
313 countries worldwide), with over 2.5 billion doses administered [38].

314

315 References

- 316 1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E et al.
317 Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2020 [cited 20 February
318 2022]. Available from: <https://ourworldindata.org/coronavirus>
- 319 2. World Bank. *World Bank Country and Lending Groups* (2022). Available at:
320 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
321 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 322 3. WHO. *Tracking SARS-CoV-2 variants* (2022). Available at:
323 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
- 324 4. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al. Experimental and in
325 Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614g Mutation in Sars-
326 Cov-2 Spike Protein. *npj Vaccines* (2020) 5(1):96. doi: 10.1038/s41541-020-00246-8.
- 327 5. Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, et al. Immunogenicity and
328 Protective Efficacy of a Highly Thermotolerant, Trimeric Sars-Cov-2 Receptor Binding
329 Domain Derivative. *ACS Infectious Diseases* (2021) 7(8):2546-64. doi:
330 10.1021/acsinfecdis.1c00276.
- 331 6. Australian Government Department of Health. *Vaxzevria (AstraZeneca)* (2022). Available at:
332 [https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/astrazeneca)
333 [vaccines/astrazeneca](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/astrazeneca)
- 334 7. Kärber G. Beitrag Zur Kollektiven Behandlung Pharmakologischer Reihenversuche. *Naunyn-*
335 *Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie* (1931) 162(4):480-
336 3. doi: 10.1007/BF01863914.
- 337 8. Sitaras I, Personal Communication (16 Feb 2022) to S.S Vasan
- 338 9. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly Accurate
339 Protein Structure Prediction with AlphaFold. *Nature* (2021) 596(7873):583-9. doi:
340 10.1038/s41586-021-03819-2.
- 341 10. Kuiper MJ, Wilson LOW, Mangalaganesh S, Lee C, Reti D, Vasan SS. “But Mouse, You Are
342 Not Alone”: On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting
343 Mice. *ILAR Journal* (2022). doi: 10.1093/ilar/ilab031.
- 344 11. Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, et al. Scalable
345 Molecular Dynamics on Cpu and Gpu Architectures with Namd. *J Chem Phys* (2020)
346 153(4):044130. doi: 10.1063/5.0014475.

Neutralization of SARS-CoV-2 Omicron


- 347 12. R-Core-Team. *R: A Language and Environment for Statistical Computing*; R Foundation for
348 Statistical Computing: Vienna, Austria, 2019. Available online: <https://www.r-project.org/>
349 13. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
350 Thrombocytopenia after Chadox1 Ncov-19 Vaccination. *New England Journal of Medicine*
351 (2021) 384(22):2092-101. doi: 10.1056/NEJMoa2104840.
352 14. Peterson-KFF Health System Tracker. *COVID-19 leading cause of death ranking* (2022).
353 Available at: <https://www.healthsystemtracker.org/>
354 15. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma
355 Neutralization of the Sars-Cov-2 Omicron Variant. *New England Journal of Medicine* (2021)
356 386(6):599-601. doi: 10.1056/NEJMc2119641.
357 16. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. Sars-Cov-2 Omicron Variant
358 Neutralization in Serum from Vaccinated and Convalescent Persons. *New England Journal of*
359 *Medicine* (2022) 386(7):698-700. doi: 10.1056/NEJMc2119236.
360 17. Fratev F. R346k Mutation in the Mu Variant of Sars-Cov-2 Alters the Interactions with
361 Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study. *Journal of*
362 *Chemical Information and Modeling* (2022) 62(3):627-31. doi: 10.1021/acs.jcim.1c01243.
363 18. CDC. *COVID Data Tracker* (2022). Available at: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#dataatracker-home)
364 [tracker/#dataatracker-home](https://covid.cdc.gov/covid-data-tracker/#dataatracker-home)
365 19. Hui KPY, Ho JCW, Cheung M-c, Ng K-c, Ching RHH, Lai K-l, et al. Sars-Cov-2 Omicron
366 Variant Replication in Human Bronchus and Lung Ex Vivo. *Nature* (2022). doi:
367 10.1038/s41586-022-04479-6.
368 20. Fischer H, Widdicombe JH. Mechanisms of Acid and Base Secretion by the Airway
369 Epithelium. *J Membr Biol* (2006) 211(3):139-50. Epub 20061107. doi: 10.1007/s00232-006-
370 0861-0.
371 21. Liu L, Iketani S, Guo Y, Chan JFW, Wang M, Liu L, et al. Striking Antibody Evasion
372 Manifested by the Omicron Variant of Sars-Cov-2. *Nature* (2021). doi: 10.1038/s41586-021-
373 04388-0.
374 22. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate Mutation Rate in the
375 Sars Coronavirus Genome and Its Implications. *BMC Evol Biol* (2004) 4:21. Epub 20040628.
376 doi: 10.1186/1471-2148-4-21.
377 23. Bar-On YM, Flamholz A, Phillips R, Milo R. Sars-Cov-2 (Covid-19) by the Numbers. *eLife*
378 (2020) 9:e57309. doi: 10.7554/eLife.57309.
379 24. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral Mutation Rates. *J Virol*
380 (2010) 84(19):9733-48. Epub 20100721. doi: 10.1128/jvi.00694-10.
381 25. Bauer DC, Tay AP, Wilson LOW, Reti D, Hosking C, McAuley AJ, et al. Supporting
382 Pandemic Response Using Genomics and Bioinformatics: A Case Study on the Emergent
383 Sars-Cov-2 Outbreak. *Transbound Emerg Dis* (2020) 67(4):1453-62. doi:
384 <https://doi.org/10.1111/tbed.13588>.
385 26. Koyama T, Platt D, Parida L. Variant Analysis of SARS-CoV-2 Genomes. *Bull World Health*
386 *Organ* (2020) 98(7):495-504. Epub 2020/06/02. doi: 10.2471/BLT.20.253591.
387 27. Australian Government Department of Health. ATAGI statement on defining 'up-to-date'
388 status for COVID-19 vaccination (2022). Available at: [https://www.health.gov.au/news/atagi-](https://www.health.gov.au/news/atagi-statement-on-defining-up-to-date-status-for-covid-19-vaccination)
389 [statement-on-defining-up-to-date-status-for-covid-19-vaccination](https://www.health.gov.au/news/atagi-statement-on-defining-up-to-date-status-for-covid-19-vaccination)
390 28. Burki TK. Fourth Dose of Covid-19 Vaccines in Israel. *The Lancet Respiratory Medicine*
391 (2022) 10(2):e19. doi: 10.1016/S2213-2600(22)00010-8.
392 29. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. 4th Dose
393 Covid Mrna Vaccines' Immunogenicity & Efficacy against Omicron Voc.
394 *medRxiv* (2022):2022.02.15.22270948. doi: 10.1101/2022.02.15.22270948.

Neutralization of SARS-CoV-2 Omicron

- 395 30. May DH, Rubin BER, Dalai SC, Patel K, Shafiani S, Elyanow R, et al. Immunosequencing
396 and Epitope Mapping Reveal Substantial Preservation of the T Cell Immune Response to
397 Omicron Generated by Sars-Cov-2 Vaccines. *medRxiv* (2021):2021.12.20.21267877. doi:
398 10.1101/2021.12.20.21267877.
- 399 31. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. Sars-Cov-2 Spike T
400 Cell Responses Induced Upon Vaccination or Infection Remain Robust against Omicron.
401 *medRxiv* (2021):2021.12.26.21268380. doi: 10.1101/2021.12.26.21268380.
- 402 32. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al.
403 Homologous and Heterologous Covid-19 Booster Vaccinations. *New England Journal of*
404 *Medicine* (2022). doi: 10.1056/NEJMoa2116414.
- 405 33. He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous Prime-Boost: Breaking the
406 Protective Immune Response Bottleneck of Covid-19 Vaccine Candidates. *Emerg Microbes*
407 *Infect* (2021) 10(1):629-37. doi: 10.1080/22221751.2021.1902245.
- 408 34. Jayaraman KS. Ferret Chosen as Animal Model to Test Coronavirus Vaccines. *Nature India*
409 (5 April 2020). Available at: <http://go.nature.com/39LGAqx>.
- 410 35. Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, et al. Chadox1 Ncov-
411 19 (Azd1222) Vaccine Candidate Significantly Reduces Sars-Cov-2 Shedding in Ferrets. *npj*
412 *Vaccines* (2021) 6(1):67. doi: 10.1038/s41541-021-00315-6.
- 413 36. Van Doremalen N, Purushotham Jyothi N, Schulz Jonathan E, Holbrook Myndi G,
414 Bushmaker T, Carmody A, et al. Intranasal Chadox1 Ncov-19/Azd1222 Vaccination Reduces
415 Viral Shedding after Sars-Cov-2 D614g Challenge in Preclinical Models. *Science*
416 *Translational Medicine* (2021) 13(607):eabh0755. doi: 10.1126/scitranslmed.abh0755.
- 417 37. Imperial College London. *Landmark coronavirus study to trial inhaled Imperial and Oxford*
418 *vaccines* (2020). Available at: [https://www.imperial.ac.uk/news/203653/landmark-](https://www.imperial.ac.uk/news/203653/landmark-coronavirus-study-trial-inhaled-imperial/)
419 [coronavirus-study-trial-inhaled-imperial/](https://www.imperial.ac.uk/news/203653/landmark-coronavirus-study-trial-inhaled-imperial/)
- 420 38. BBC. *AstraZeneca vaccine: Did nationalism spoil UK's 'gift to the world'?* (2022). Available
421 at: <https://www.bbc.com/news/health-60259302>
- 422 39. Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically
423 disordered proteins. *Nature Methods* (2017) 14, 71-73, doi:10.1038/nmeth.4067
- 424 40. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
425 *Science* (2020) 367, 1260-1263 doi: 10.1126/science.abb2507
- 426 41. Watanabe Y, Allen, JD, Wrapp, J, McLellan, JS, Crispin, M. Site-specific glycan analysis of
427 the SARS-CoV-2 spike *Science* (2020) 369(6501):330-333. doi: 10.1126/science.abb9983.
- 428 42. Humphrey, W., Dalke, A. and Schulten, K., "VMD - Visual Molecular Dynamics", *J. Molec.*
429 *Graphics*, 1996, vol. 14, pp. 33-38.41

Neutralization of SARS-CoV-2 Omicron

430 Figures 1-4




431

432 **Figure 1: Box Plots Showing 50% Neutralisation Titres (NT₅₀) Against SARS-CoV-2 Variants**
433 **of Concern with Plasma from Human Volunteers**

434 Neutralisation of VIC31, Delta, and Omicron by human donor samples collected at different
435 timepoints following vaccination with AstraZeneca (A), Moderna (B), or Pfizer (C) COVID-19
436 vaccines. The titres are shown in Log₂ scale on the y-axis.

Neutralization of SARS-CoV-2 Omicron




437

438 **Figure 2: Box Plots Showing 50% Neutralization Titres (NT₅₀) Against SARS-CoV-2 Variants**
439 **of Concern Assessed by Sex of Donors**

440 Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or
441 Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron
442 (iii), with titres assessed with respect to sex. The titres are shown in Log₂ scale in the y-axis. The
443 ANOVA results of pairwise comparison between pre and post vaccinated sera for the different sexes
444 are presented as adj p-values using Bonferroni post hoc test.

Neutralization of SARS-CoV-2 Omicron

445




446

447 **Figure 3: Box Plots Showing NT₅₀ Values Against SARS-CoV-2 Variants of Concern Assessed**
448 **by Age Group**

449 Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or
450 Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron
451 (iii), with titres assessed with respect to age group. The titres are shown in Log₂ scale in the y-axis.
452 The ANOVA results of pairwise comparison between pre and post vaccinated sera for the different
453 sexes are presented as adj p-values using Bonferroni post hoc test.

Neutralization of SARS-CoV-2 Omicron



454

455 **Figure 4: Structure of SARS-CoV-2 Spike Protein and Mutations of Interest**

456 **A.** The Omicron spike protein with mutations shown in pink. A single S1 domain is highlighted in
457 blue with the receptor binding domain (RBD) in the 'up' configuration is highlighted in cyan.
458 Glycosylation is shown as green lines. **B. & C.** Comparison of the RBD in the Omicron and Delta
459 variants, 15 mutations are observed in Omicron while only 2 in the Delta variant.

Neutralization of SARS-CoV-2 Omicron

460 **Tables 1 & 2**

461 **Table 1: Information on Human Participants, Vaccines, and Blood Collection Schedule**

		AstraZeneca	Moderna	Pfizer
Donor		n=6	n=12	n=15
Sex	Male	n=3	n=6	n=5
	Female	n=3	n=6	n=10*
Age [Median (Range)]	Male	58 (57-65)	41.5 (29-70)	31 (29-35)
	Female	57 (31-59)	38.5 (27-47)	33.5 (25-57)
	Overall	57.5 (31-65)	38.5(27-70)	33 (25-57)
Samples Used	pre-1 st Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
	2w Post-2 nd Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
	6mo Post-2 nd Dose			n=15 (5M, 10F)
	2w Post-3 rd Dose			n=6 (3M, 3F)

462 *For pre-1st dose and 2w post-2nd dose the samples are gender balanced.

463

464 **Table 2: Sex-Based Mean and Standard Deviation for VNT Titres Against SARS-CoV-2**
 465 **Variants for Human Subjects Vaccinated with Different COVID-19 Vaccines.**

Vaccine	Sex	Estimates	VIC31				Delta				Omicron			
			1	2	3	4	1	2	3	4	1	2	3	4
AstraZeneca	Female	Mean	2.32	3.46	X	X	2.32	2.32	X	X	2.32	2.32	X	X
		SD	0.00	0.00	X	X	0.00	0.00	X	X	0.00	0.00	X	X
	Male	Mean	2.32	5.04	X	X	2.32	2.82	X	X	2.32	2.32	X	X
		SD	0.00	1.01	X	X	0.00	0.86	X	X	0.00	0.00	X	X
	All	Mean	2.32	4.25	X	X	2.32	2.57	X	X	2.32	2.32	X	X
		SD	0.00	1.08	X	X	0.00	0.61	X	X	0.00	0.00	X	X
Moderna	Female	Mean	2.32	7.16	X	X	2.32	5.99	X	X	2.32	2.57	X	X
		SD	0.00	1.11	X	X	0.00	0.76	X	X	0.00	0.61	X	X
	Male	Mean	2.32	6.93	X	X	2.32	5.05	X	X	2.32	2.82	X	X
		SD	0.00	1.17	X	X	0.00	1.28	X	X	0.00	0.80	X	X
	All	Mean	2.32	7.04	X	X	2.32	5.52	X	X	2.32	2.69	X	X
		SD	0.00	1.09	X	X	0.00	1.12	X	X	0.00	0.69	X	X
Pfizer	Female	Mean	2.32	7.22	3.75	7.93	2.32	6.36	3.37	7.39	2.32	2.73	2.32	4.59
		SD	0.00	1.08	0.66	0.38	0.00	1.04	0.79	0.51	0.00	0.67	0.00	0.71
	Male	Mean	2.32	6.76	4.61	9.49	2.32	5.76	4.34	9.27	2.32	2.49	2.32	6.63
		SD	0.00	0.92	0.71	0.67	0.00	1.06	0.97	0.77	0.00	0.38	0.00	1.17
	All	Mean	2.32	7.07	4.04	8.71	2.32	6.15	3.70	8.32	2.32	2.65	2.32	5.60
		SD	0.00	1.02	0.78	0.98	0.00	1.05	0.95	1.19	0.00	0.59	0.00	1.40

466 All VNT titres expressed as Log2 values. Values indicated as 2.32 represent titres below the assay detection limit. SD =
 467 Standard Deviation of Mean; 1 =-1st dose; 2 = 2wk-2nd dose; 3 = 6mo-2nd dose and 4 = 2wk-3rd dose. X = sample not
 468 available for analysis

469 **Data Availability Statement**

470 The original contributions presented in the study are included in the article/Supplementary Material.
471 Further inquiries can be directed to the corresponding author.

472 **Ethics Statement**

473 The study protocols were approved by institutional ethics committees of the Peter Doherty Institute,
474 Melbourne Australia [University of Melbourne Central Human Research Ethics Committee (2021-
475 21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID 2021_123_RR).
476 The reference serum for the neutralisation assay was derived from an animal study reviewed and
477 approved by CSIRO ACDP Animal Ethics Committee (AEC 2004).

478 **Author Contributions**

479 NBS designed the study with PJvV, AJM, SMG and SSV. PJvV and AJM performed the experiments
480 with MPB, SR and SG. NBS and SMG analysed the experimental data and provided statistical
481 interpretations, with inputs from PJvV, AJM, TWD and SSV. MJK performed biomolecular
482 modelling and provided structural interpretations. LC and JDD isolated the virus variants, which
483 were sequenced by KRB and MT. JAJ, SJK and AKW provided the human plasma samples and
484 obtained the necessary funding for the same. SM, SC and SSV analysed the health economic
485 implications. NBS, PJvV, AJM, MJK, SM, SC and SSV co-wrote the manuscript, and all authors
486 contributed to revisions and creation of the final version. SV conceived the project and
487 obtained funding.

488 **Funding**

489 This work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO's Precision
490 Health & Responsible Innovation Future Science Platforms, National Health and Medical Research
491 Council (grant MRF2009092), and United States Food and Drug Administration (FDA) Medical
492 Countermeasures Initiative (contract 75F40121C00144). J.A.J., S.J.K. and A.K.W. are grateful to the
493 National Health and Medical Research Council (for grants GNT2002073, MRF2005544,
494 GNT1149990, fellowships and an investigator grant). We also thank the Victorian Government,
495 especially the Victorian Department of Health and Human Services, the major funder of the Victorian
496 Infectious Diseases Reference Laboratory and Barwon Health. The article reflects the views of the
497 authors and does not represent the views or policies of the funding agencies including the FDA.

498 **Conflict of Interest**

499 All claims expressed in this article are solely those of the authors and do not necessarily represent
500 those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any
501 product that may be evaluated in this article, or claim that may be made by its manufacturer, is not
502 guaranteed or endorsed by the publisher.

503 **Acknowledgments**

504 The authors are grateful for support from Professor Sharon Lewin, Professor Deborah Williamson
505 and colleagues at the Peter Doherty Institute for Infection and Immunity
506 (<https://www.grid.ac/institutes/grid.483778.7>) and the CSIRO's Australian Centre for Disease
507 Preparedness (ACDP; <https://www.grid.ac/institutes/grid.413322.5>), especially Dr Daniel Layton and

Neutralization of SARS-CoV-2 Omicron

508 Kristen McAuley. We thank Dr Amy Shurtleff of the Coalition for Epidemic Preparedness
509 Innovations and the University of Oxford's Professors Teresa Lambe and Dame Sarah Gilbert for
510 access to positive control ferret sera from their study (CSIRO ACDP Animal Ethics Committee
511 Approval Reference: AEC 2004).

Neutralization of SARS-CoV-2 Omicron

512 **Supplementary Material**

513 **Supplementary Tables S1 to S5**

514 **Supplementary Table S1: Comparison for NT50 values on 2nd-2wk**

Comparison	Variant	Estimate (‘adjusted’ p-value)
Pfizer vs Moderna	VIC31	p=1.00
Pfizer vs Moderna	Omicron	p=1.00
Pfizer vs Moderna	Delta	p=0.48

515

516 **Supplementary Table S2: One-way ANOVA results for vaccines, variants, sex, age and day post vaccination/boosters**

517

Vaccine	Variable	F-value	p-value	Significance
Pfizer	Sex	2.421	0.122	NS
	Age	0.859	0.355	NS
	Day post vaccination/booster	73.84	<2e-16	***
	Variant	16.61	3.05E-07	***
Moderna	Sex	0.104	0.748	NS
	Age	0.074	0.929	NS
	Day post vaccination/booster	64.56	1.58E-11	***
	Variant	8.839	0.000382	***
AstraZeneca	Sex	1.497	0.230	NS
	Age	1.401	0.261	NS
	Day post vaccination/booster	7.722	0.00882	**
	Variant	5.744	0.00724	**

518

519 **Supplementary Table S3: Two-way ANOVA results of interactions for vaccines, variants, sex, age and day post vaccination/boosters**

520

Vaccine	Factor	Factor	F-value	p-value	Significance
Pfizer	Variant	Sex	0.047	0.954	NS
		Age	0.018	0.983	NS
		Day post vaccination/booster	26.31	<2E-16	***
Moderna	Variant	Sex	0.158	0.583	NS
		Age	0.052	0.995	NS
		Day post vaccination/booster	59.91	1.46E-15	***
AstraZeneca	Variant	Sex	0.872	0.429	NS
		Age	0.507	0.731	NS
		Day post vaccination/booster	13.00	8.70E-05	***

521

522

Neutralization of SARS-CoV-2 Omicron

523 **Supplementary Table S4: Linear Mixed Models (lm) for analysis of variance between variables**

Model	df	AIC	Forward selection
Titre~1	2	1124.513	No
Titre~Sex	3	1125.835	No
Titre~Age	4	1123.255	No
Titre~Day	5	939.998	Yes
Titre~Vaccine	4	113.991	No
Titre~Variant	4	1081.153	No
Titre~Day+Sex	5	941.652	No
Titre~Day+Age	6	934.913	No
Titre~Day+Vaccine	7	926.686	No
Titre~Day+Variant	7	833.830	Yes
Titre~Day+Variant+Sex	8	835.303	No
Titre~Day+Variant+Age	9	823.844	No
Titre~Day+Variant+Vaccine	9	810.945	Yes
Titre~Day+Variant+Vaccine+Sex	10	811.523	No
Titre~Day+Variant+Vaccine+Age	11	809.378	Yes

524

525 **Supplementary Table S5: Summary statistics for model lm(Titre~Day+Variant+Vaccine+Age)**

	Estimate	Std. Error	t-value	Pr(> t)	Signif.
(Intercept)	1.626	0.2327	6.989	2.49E-11	***
2wk-2 nd dose	2.4878	0.1585	15.696	<2.00E-16	***
6mo-2 nd dose	0.7876	0.2185	3.605	0.000376	***
2wk-3 rd dose	5.0109	0.2988	16.769	<2.00E-16	***
Omicron	-1.4357	0.1691	-8.491	1.82E-15	***
VIC31	0.5685	0.1691	3.362	0.000894	***
Moderna	0.8981	0.2336	3.844	0.000153	***
Pfizer	0.9608	0.2379	4.039	7.14E-05	***
Senior	0.2599	0.2972	0.875	0.38268	
Young	0.363	0.1575	2.305	0.021988	*

526

527

Neutralization of SARS-CoV-2 Omicron

528 **Supplementary Text S1: Summary statistics for model**
 529 **lmer(Titre~Day+Variant+Vaccine+Age+(1|subject))**

530 Linear mixed model fit by REML [lmerMod]
 531 Formula: titre ~ variant + day + vaccine + (1 | subject)
 532 REML criterion at convergence: 807.3

533 Scaled residuals:

Min	1Q	Median	3Q	Max
-2.3131	-0.8867	-0.0175	0.8057	3.4851

534 Random effects:

Groups	Name	Variance	Std.Dev.
subject	(Intercept)	0.000	0.000
	Residual	1.260	1.123

536 Number of obs: 261, groups: subject, 33

537 Fixed effects:

	Estimate	Std. Error	t-value
(Intercept)	1.7299	0.2259	7.658
Omicron	-1.4357	0.1702	-8.434
VIC31	0.5685	0.1702	3.34
2wk-2 nd dose	2.4878	0.1596	15.591
6mo-2 nd dose	0.7876	0.2199	3.581
2wk-3 rd dose	4.9867	0.3006	16.587
Moderna	1.0191	0.2292	4.447
Pfizer	1.1232	0.2214	5.074

539 Correlation of Fixed Effects:

	(Intr)	Omicron	VIC31	2wk-2 nd dose	6mo-2 nd dose	2wk-3 rd dose	Moderna
Omicron	-0.377						
VIC31	-0.377	0.500					
2wk-2 nd dose	-0.353	0.000	0.000				
6mo-2 nd dose	-0.128	0.000	0.000	0.363			
2wk-3 rd dose	-0.094	0.000	0.000	0.265	0.308		
Moderna	-0.676	0.000	0.000	0.000	0.000	0.000	
Pfizer	-0.700	0.000	0.000	0.000	-0.288	-0.210	0.690

541
542

543 **Supplementary Methods**

544

545 ***in silico* Modelling**

546 Molecular simulations were performed using NAMD2.14 with CHARMM36m forcefield [39]
547 employing a TIP3 water model. The Spike model was based on the pdb structure 6VSB3 [40], built
548 with additions segments predicted with AlphaFold. The Spike protein only included residues 13 to
549 1160 (omitting transmembrane domain, to reduce the simulation size). Glycosylation of the Spike
550 protein was manually constructed using Visual Molecular Dynamics (VMD) guided by glycan
551 analysis [41]. Omicron models were constructed in two conformations, all RBD ‘down’, and 2 RBD
552 ‘down’ one RBD ‘up’. Both models included an ACE2 domain in the expected binding position.


553 Simulations were run with Periodic Boundary Conditions ‘PBCs’ using the NPT ensemble at
554 310K and 1 bar pressure employing Langevin dynamics. The PBCs were constant in the XY
555 dimensions. Long-range Coulomb forces were computed with the Particle Mesh Ewald method with
556 a grid spacing of 1 Å. 2 fs timesteps were used with non-bonded interactions calculated every 2 fs
557 and full electrostatics every 4 fs while hydrogens were constrained with the ‘SHAKE’ algorithm. The
558 cut-off distance was 12 Å with a switching distance of 10 Å and a pair-list distance of 14 Å. Pressure
559 was controlled to 1 atmosphere using the NoséHoover Langevin piston method employing a piston
560 period of 100 fs and a piston decay of 50 fs. Trajectory frames were captured every 100 ps.
561 Simulations were performed for at least 200 nanoseconds. Trajectories were visualized and analysed
562 using VMD [42].

563

564 **Supplementary Figures**

565

566



567

568

569

570

571 **Supplementary Figure S1.** a) Omicron spike protein binding to ACE2 domain (shown in yellow).


572 S1 domain shown in blues, with the receptor binding domain shown in cyan. Glycosylation is shown

573 as green sticks. b) close up of the ACE2 binding interface of Omicron spike RBD showing the

574 interaction of contacting residues.

575

Neutralization of SARS-CoV-2 Omicron



576

577 **Supplementary Figure S2.** Close up of Omicron mutations in adjacent receptor binding domains
578 (pink and blue) in 'down' position showing the close proximity of residues L371, P373 and F375 on
579 the blue domain to the adjacent H505. This complementary arrangement may have influence on the
580 RBD 'up'/'down' transitions by pH dependant ionization of H505.

581